Professor Alex Rothman

MA, BM BCh, MRes, PhD, MRCP, EEGC

Clinical Medicine, School of Medicine and Population Health

Professor of Cardiology

Honorary Consultant Cardiologist

a.rothman@sheffield.ac.uk
+44 114 215 9521

The Medical School

Full contact details

Professor Alex Rothman
Clinical Medicine, School of Medicine and Population Health
The Medical School
Beech Hill Road
Sheffield
S10 2RX

Profile

For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk

I trained in medicine at Cambridge and Oxford and joined the University of Sheffield in 2008 as an Academic Clinical Fellow working as part of a team investigating the therapeutic tractability of inflammation in patients suffering heart attacks (the MRC ILA Heart study).

Through my MRC Clinical Research Training Fellowship I developed an interest in the pathology and treatment of cardiovascular diseases and have been closely involved in studies investigating new therapies and devices for the treatment of pulmonary arterial hypertension, atherosclerosis and heart failure.

I am currently a Wellcome Trust Career Development Fellow and an Honorary Consultant Cardiologist at Sheffield Teaching Hospitals NHS Trust.

Research interests

My research interests are the pathology and treatment of cardiovascular and pulmonary vascular diseases.

The MRC ILA Heart study was the first randomised study to demonstrate the therapeutic tractability of inflammatory signalling in coronary artery disease. Findings were published in the European Heart Journal and the New England Journal of Medicine and validated by CANTOS, a phase III study of the interleukin-1 beta targeted therapy Canakinumab that demonstrated a reduction in recurrent cardiac events.

My current work focuses on the pathology of pulmonary arterial hypertension and the development of novel therapeutic strategies. Recent pre-clinical studies have led to early phase clinical studies of pulmonary artery denervation, implantable pulmonary artery pressure monitors and new drug studies.

Current projects:

Wellcome Trust Clinical Research Career Development Fellowship: Determining Novel SMURF1 Signalling Pathways and Precision Medicine Strategies in Patients with Pulmonary Arterial Hypertension, £460,409.
MRC Confidence in Concepts, The Feasibility of Novel Clinical Trial Infrastructure, Design and Technology for Early Phase Studies in Patients with Pulmonary Arterial Hypertension (FIT-PH), £65,610 (PI)
British Heart Foundation, Development of a Prototype Pericardial Left Ventricular Assist Device, £249,967 (Co-I)
Medtronic Inc. Non-invasive phenotyping of arrhythmias in pulmonary arterial hypertension, £200,000
Association of Physicians of Great Britain and Ireland Young Investigator Award, £19,973
Academy of Medical Sciences, Starter Grants for Clinical Lecturers: Inhibition of SMURF1 for the Treatment of Pulmonary Arterial Hypertension, £30,000
EPSRC/HEFCE and Endotronix: Intra-arterial Pulmonary Artery Pressure Monitoring in Pulmonary Hypertension: Re-defining Clinical Measurement of Treatment Effect and Disease Progression, £84,711
TROPHY: Therapeutic Intravascular Ultrasound for the treatment of pulmonary arterial hypertension (https://clinicaltrials.gov/ct2/show/NCT02516722)
SIRONA: A Prospective, Multi-Center, Open-Label, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella Heart Failure System in NYHA Class III Heart Failure Patients. (https://clinicaltrials.gov/ct2/show/NCT03375710)

Publications

Show: Featured publications All publications

Featured publications

Journal articles

Rothman A, Kiely D, Vachiery J-L, Howard LS, MIkhail GW, Lang IM, Jonas M, Shav D, Shabtay O, Avriel A , Lewis GD et al (2020) Intravascular ultrasound pulmonary artery denervation to treat pulmonary arterial hypertension (TROPHY1): multicenter, early feasibility study. JACC: Cardiovascular Interventions, 13(8), 989-999. View this article in WRRO
Toshner M & Rothman A (2020) IL-6 in pulmonary hypertension: why novel is not always best. European Respiratory Journal, 55(4), 2000314-2000314.
Lewis RA, Johns CS, Cogliano M, Capener D, Tubman E, Elliot CA, Charalampopoulos A, Sabroe I, Thompson AAR, Billings CG , Hamilton N et al (2020) Identification of cardiac MRI thresholds for risk stratification in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine, 201(4), 458-468. View this article in WRRO
Rothman AMK, MacFadyen J, Thuren T, Webb A, Harrison DG, Guzik TJ, Libby P, Glynn RJ & Ridker PM (2020) Effects of interleukin-1β Inhibition on blood pressure, incident hypertension, and residual inflammatory risk. Hypertension, 75(2), 477-482. View this article in WRRO
Arnold ND, Pickworth JA, West LE, Dawson S, Carvalho JA, Casbolt H, Braithwaite AT, Iremonger J, Renshall L, Germaschewski V , McCourt M et al (2019) A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension. Nature Communications, 10(1). View this article in WRRO
Middleton JT, Maulik A, Lewis R, Kiely DG, Toshner M, Charalampopoulos A, Kyriacou A & Rothman A (2019) Arrhythmic burden and outcomes in pulmonary arterial hypertension. Frontiers in Medicine, 6. View this article in WRRO
Rothman A, Jonas M, Castel D, Tzafriri AR, Traxler H, Shav D, Leon MB, Ben-Yehuda O & Rubin L (2019) Pulmonary artery denervation using catheter based ultrasonic energy.. EuroIntervention. View this article in WRRO
Billings CG, Lewis R, Hurdman JA, Condliffe R, Elliot C, Thompson AAR, Smith IA, Austin M, Armstrong IJ, Hamilton N , Charalampopoulos A et al (2019) Express: The incremental shuttle walk test predicts mortality in non-group 1 pulmonary hypertension: results from the ASPIRE Registry.. Pulmonary Circulation. View this article in WRRO
Quadery SR, Swift AJ, Billings C, Thompson AAR, Elliot CA, Hurdman J, Charalampopoulos A, Sabroe I, Armstrong I, Hamilton N , Sephton P et al (2018) The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 52(3). View this article in WRRO
Crossman D & Rothman AMK (2018) Interleukin-1 beta inhibition with canakinumab and reducing lung cancer—subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS). Journal of Thoracic Disease, 10(S26), S3084-S3087.
Alfaidi MA, Chamberlain J, Rothman A, Crossman D, Villa‐Uriol MC, Hadoke P, Wu J, Schenkel T, Evans PC & Francis SE (2018) Dietary Docosahexaenoic Acid Reduces Oscillatory Wall Shear Stress, Atherosclerosis, and Hypertension, Most Likely Mediated via an IL‐1–Mediated Mechanism. Journal of the American Heart Association, 7(13). View this article in WRRO
Rothman AMK, Morton AC, Crossman DC & Investigators MRC-ILAH (2018) Canakinumab for Atherosclerotic Disease. The New England journal of medicine, 378(2), 196-200. View this article in WRRO
Rothman AM & Crossman D (2017) The Canakinumab Antiinflammatory Thrombosis Outcome Study Trial—The Starting Gun Has Fired. Journal of Thoracic Disease, 9, 4922-4925. View this article in WRRO
Swift AJ, Capener D, Johns C, Hamilton N, Rothman A, Elliot C, Condliffe R, Charalampopoulos A, Rajaram S, Lawrie A , Campbell MJ et al (2017) Magnetic Resonance Imaging in the Prognostic Evaluation of Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 196(2). View this article in WRRO
Billings CG, Hurdman JA, Condliffe RA, Elliot CA, Smith IA, Austin M, Armstrong IJ, Hamilton N, Charalampopoulos A, Sabroe I , Swift AJ et al (2017) Incremental Shuttle Walking Test Distance and Autonomic Dysfunction Predict Survival in Pulmonary Arterial Hypertension. The Journal of Heart and Lung Transplantation. View this article in WRRO
Rothman AM, Rowlands DJ & Lawrie A (2016) miRNA-140-5p: new avenue for pulmonary arterial hypertension drug development?. Epigenomics. View this article in WRRO
Rothman AM, Arnold N, Pickworth J, Iremonger J, Ciuclan L, Allan R, Guth-Gundel S, Southwood M, Morrell N, Thomas M , Francis S et al (2016) MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension. Journal of Clinical Investigation, 126(7), 2495-2508. View this article in WRRO
Zhou L, Zhang J, Jiang X-M, Xie D-J, Wang J-S, Li L, Li B, Wang Z-M, Rothman AMK, Lawrie A & Chen S-L (2015) Pulmonary Artery Denervation Attenuates Pulmonary Arterial Remodeling in Dogs With Pulmonary Arterial Hypertension Induced by Dehydrogenized Monocrotaline. JACC: Cardiovascular Interventions, 8(15), 2013-2023.
Rothman AMK, Arnold ND, Chang W, Watson O, Swift AJ, Condliffe R, Elliot CA, Kiely DG, Suvarna SK, Gunn J & Lawrie A (2015) Pulmonary Artery Denervation Reduces Pulmonary Artery Pressure and Induces Histological Changes in an Acute Porcine Model of Pulmonary Hypertension. Circulation: Cardiovascular Interventions, 8(11), e002569-e002569. View this article in WRRO
Chen S-L, Zhang H, Xie D-J, Zhang J, Zhou L, Rothman AMK & Stone GW (2015) Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes. Circulation: Cardiovascular Interventions, 8(11). View this article in WRRO
Rothman AMK, Chico TJA & Lawrie A (2014) MicroRNA in pulmonary vascular disease.. Prog Mol Biol Transl Sci, 124, 43-63.
Morton A, Rothman AM, Greenwood JP, Gunn JP, Chases A, Clarke B, Hall AS, Fox K, Folev C, Banya W , Wang D et al (2013) The Effect of Interleukin-1 Receptor Antagonist Therapy on Markers of Inflammation in Non-ST Elevation Acute Coronary Syndromes: The MRC-ILA Heart Study. CIRCULATION, 128(22). View this article in WRRO
Watson O, Novodvorsky P, Gray C, Rothman AMK, Lawrie A, Crossman DC, Haase A, McMahon K, Gering M, Van Eeden FJM & Chico TJA (2013) Blood flow suppresses vascular Notch signalling via dll4 and is required for angiogenesis in response to hypoxic signalling.. Cardiovasc Res, 100(2), 252-261. View this article in WRRO
Wang T, Waters CT, Rothman AMK, Jakins TJ, Römisch K & Trump D (2002) Intracellular retention of mutant retinoschisin is the pathological mechanism underlying X-linked retinoschisis. Human molecular genetics, 11(24), 3097-3105.
Mullens W, Sharif F, Dupont M, Rothman AMK & Wijns W () Digital health care solution for proactive heart failure management with the Cordella Heart Failure System : results of the SIRONA first‐in‐human study. European Journal of Heart Failure. View this article in WRRO
Novodvorsky P, Watson O, Gray C, Wilkinson RN, Reeve S, Smythe C, Beniston R, Plant K, Maguire R, M. K. Rothman A , Elworthy S et al () klf2ash317 Mutant Zebrafish Do Not Recapitulate Morpholino-Induced Vascular and Haematopoietic Phenotypes. PLoS ONE, 10(10). View this article in WRRO

All publications

Journal articles

Smith H, Thompson AAR, Akil M, Alabed S, Charalampopoulos A, Dwivedi K, Elliot CA, Hameed A, Haque A, Hamilton N , Hill C et al (2024) The spectrum of systemic sclerosis-associated pulmonary hypertension: Insights from the ASPIRE registry. The Journal of Heart and Lung Transplantation, 43(10), 1629-1639. View this article in WRRO
Lawrie A, Hamilton N, Wood S, Exposto F, Muzwidzwa R, Raiteri L, Beaudet A, Muller A, Sauter R, Pillai N & Kiely DG (2024) Association of risk assessment at diagnosis with healthcare resource utilization and health‐related quality of life outcomes in pulmonary arterial hypertension. Pulmonary Circulation, 14(3). View this article in WRRO
Ghobrial M, Haley H, Gosling R, Taylor DJ, Richardson J, Morgan K, Barmby D, Iqbal J, Krishnamurthy A, Singh R , Conway D et al (2024) Modelled impact of virtual fractional flow reserve in patients undergoing coronary angiography (VIRTU-4). Heart. View this article in WRRO
Chatters R, Dimairo M, Cooper C, Ditta S, Woodward J, Biggs K, Ogunleye D, Thistlethwaite F, Yap C & Rothman A (2024) Exploring the barriers to, and importance of, participant diversity in early-phase clinical trials: an interview-based qualitative study of professionals and patient and public representatives. BMJ Open, 14(3). View this article in WRRO
Varian F, Dick J, Battersby C, Roman S, Ablott J, Watson L, Binmahfooz S, Zafar H, Colgan G, Cannon J , Suntharalingam J et al (2024) Pulmonary hypertension: intensification and personalization of combination Rx (PHoenix): a phase IV randomized trial for the evaluation of dose‐response and clinical efficacy of riociguat and selexipag using implanted technologies. Pulmonary Circulation, 14(1). View this article in WRRO
Durrington C, Hurdman JA, Elliot CA, Maclean R, Van Veen J, Saccullo G, De-Foneska D, Swift AJ, Smitha R, Hill C , Thomas S et al (2024) Systematic pulmonary embolism follow-up increases diagnostic rates of chronic thromboembolic pulmonary hypertension and identifies less severe disease: results from the ASPIRE Registry. European Respiratory Journal, 63(3). View this article in WRRO
Rommel K-P, Hobohm L, Rothman AMK & Lurz P (2024) Radiation to Illuminate the Path of Neuromodulation for Pulmonary Hypertension. JACC: Basic to Translational Science, 9(2), 257-259.
Dwivedi K, Sharkey M, Delaney L, Alabed S, Rajaram S, Hill C, Johns C, Rothman A, Mamalakis M, Thompson AAR , Wild J et al (2024) Improving Prognostication in Pulmonary Hypertension Using AI-quantified Fibrosis and Radiologic Severity Scoring at Baseline CT. Radiology, 310(2).
Kiely DG, Hamilton N, Wood S, Durrington C, Exposto F, Muzwidzwa R, Raiteri L, Beaudet A, Muller A, Sauter R , Pillai N et al (2024) Risk assessment and real-world outcomes in chronic thromboembolic pulmonary hypertension: insights from a UK pulmonary hypertension referral service. BMJ Open, 14(1). View this article in WRRO
Grafton-Clarke C, Matthews G, Gosling R, Swoboda P, Rothman A, Wild JM, Kiely DG, Condliffe R, Alabed S, Swift AJ & Garg P (2023) The left atrial area derived cardiovascular magnetic resonance left ventricular filling pressure equation shows superiority over integrated echocardiography. Medicina, 59(11). View this article in WRRO
Grafton-Clarke C, Matthews G, Gosling R, Swoboda P, Rothman A, Wild JM, Kiely DG, Condliffe R, Alabed S, Swift AJ & Garg P (2023) The Left Atrial Area Derived Cardiovascular Magnetic Resonance Left Ventricular Filling Pressure Equation Shows Superiority over Integrated Echocardiography. Medicina (Kaunas, Lithuania), 59(11).
Alabed S, Garg P, Alandejani F, Dwivedi K, Maiter A, Karunasaagarar K, Rajaram S, Hill C, Thomas S, Gossling R , Sharkey MJ et al (2023) Establishing minimally important differences for cardiac MRI end-points in pulmonary arterial hypertension. European Respiratory Journal, 62(2), 2202225-2202225.
Williams GJ, Al-Baraikan A, Rademakers FE, Ciravegna F, van de Vosse FN, Lawrie A, Rothman A, Ashley EA, Wilkins MR, Lawford PV , Omholt SW et al (2023) Wearable technology and the cardiovascular system: the future of patient assessment. The Lancet Digital Health, 5(7), e467-e476.
Alkhanfar D, Dwivedi K, Alandejani F, Shahin Y, Alabed S, Johns C, Garg P, Thompson AAR, Rothman AMK, Hameed A , Charalampopoulos A et al (2023) Non-invasive detection of severe PH in lung disease using magnetic resonance imaging. Frontiers in Cardiovascular Medicine, 10.
Rothman AMK, Zafar H, Sandy R, Wright C, Mitra S, Ebah L, Ilyas D, Hanumapura P, Sebastien S, Khalifa A , Passman J et al (2023) A Subcutaneous Multiparameter Sensor With Integrated Interstitial Fluid Pressure Measurement for Remote Heart Failure Monitoring. JACC: Basic to Translational Science, 8(4), 386-388.
Elamin N, Ow KW, Parker WAE, Nelson TA, Middle J, Hanson J, Moyle B, Krishnamurthy A, Barmby D, Morgan K , Adam Z et al (2022) Oral Presentation No. 84 Initial clinical experience with 6-hour enoxaparin regimen in opiate-treated patients undergoing primary percutaneous coronary intervention. Cardiovascular Research, 118(Supplement_2).
Alabed S, Alandejani F, Dwivedi K, Karunasaagarar K, Sharkey M, Garg P, de Koning PJH, Tóth A, Shahin Y, Johns C , Mamalakis M et al (2022) Validation of Artificial Intelligence Cardiac MRI Measurements: Relationship to Heart Catheterization and Mortality Prediction. Radiology, 304(3), E56-E56.
Sammut MA, Condliffe R, Elliot C, Hameed A, Lewis R, Kiely DG, Kyriacou A, Middleton JT, Raithatha A, Rothman A , Thompson AAR et al (2022) Atrial flutter and fibrillation in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension in the ASPIRE registry: Comparison of rate versus rhythm control approaches. International Journal of Cardiology.
Goh ZM, Balasubramanian N, Alabed S, Dwivedi K, Shahin Y, Rothman AMK, Garg P, Lawrie A, Capener D, Thompson AAR , Alandejani F et al (2022) Right ventricular remodelling in pulmonary arterial hypertension predicts treatment response.. Heart.
Garg P, Gosling R, Swoboda P, Jones R, Rothman A, Wild JM, Kiely DG, Condliffe R, Alabed S & Swift AJ (2022) Cardiac magnetic resonance identifies raised left ventricular filling pressure: prognostic implications.. Eur Heart J.
Alabed S, Uthoff J, Zhou S, Garg P, Dwivedi K, Alandejani F, Gosling R, Schobs L, Brook M, Capener D , Johns C et al (2022) Machine learning cardiac-MRI features predict mortality in newly diagnosed pulmonary arterial hypertension. European Heart Journal - Digital Health. View this article in WRRO
Alandejani F, Alabed S, Garg P, Goh ZM, Karunasaagarar K, Sharkey M, Salehi M, Aldabbagh Z, Dwivedi K, Mamalakis M , Metherall P et al (2022) Training and clinical testing of artificial intelligence derived right atrial cardiovascular magnetic resonance measurements. Journal of Cardiovascular Magnetic Resonance, 24(1).
Kariotis S, Jammeh E, Swietlik EM, Pickworth JA, Rhodes CJ, Otero P, Wharton J, Iremonger J, Dunning MJ, Pandya D , Mascarenhas TS et al (2021) Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. Nature Communications, 12. View this article in WRRO
Wilkins MR, Mckie MA, Law M, Roussakis AA, Harbaum L, Church C, Coghlan JG, Condliffe R, Howard LS, Kiely DG , Lordan J et al (2021) Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single-arm efficacy. Pulmonary Circulation, 11(4). View this article in WRRO
Webb A, Werring D, Dawson J, Rothman A, Lawson A & Wartolowska K (2021) Design of a randomised, double-blind, crossover, placebo-controlled trial of effects of sildenafil on cerebrovascular function in small vessel disease: Oxford haemodynamic adaptation to reduce pulsatility trial (OxHARP). European Stroke Journal, 6(3), 283-290. View this article in WRRO
Errington N, Iremonger J, Pickworth JA, Kariotis S, Rhodes CJ, Rothman AMK, Condliffe R, Elliot CA, Kiely DG, Howard LS , Wharton J et al (2021) A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach. EBioMedicine, 69, 103444-103444.
Webb A, Werring D, Dawson J, Rothman A, Lawson A & Wartolowska K (2021) Design of a randomised, double-blind, crossover, placebo-controlled trial of effects of sildenafil on cerebrovascular function in small vessel disease: Oxford haemodynamic adaptation to reduce pulsatility trial (OxHARP). European stroke journal, 6(3), 283-290.
Gosling DRC, Adam Z, Barmby DS, Iqbal J, Morgan KP, Richardson JD, Rothman AMK, Lawford PV, Hose DR, Gunn JP & Morris PD (2021) The Impact of Virtual Fractional Flow Reserve and Virtual Coronary Intervention Upon Treatment Decisions in the Cardiac Catheter Laboratory. Canadian Journal of Cardiology.
Garg P, Lewis RA, Johns CS, Swift AJ, Capener D, Rajaram S, Thompson AAR, Condliffe R, Elliot CA, Charalampopoulos A , Hameed AG et al (2021) Cardiovascular magnetic resonance predicts all-cause mortality in pulmonary hypertension associated with heart failure with preserved ejection fraction.. Int J Cardiovasc Imaging.
Premawardhana A, Lodge A, Sachdev S, Karamanavi E, Kotecha D, Lees J, Mariscalco G, Rothman A, Gunn J, Samara-Ratna P & Adlam D (2021) Preclinical testing of a novel pericardial left ventricular assist device (PALVAD). European Heart Journal Acute Cardiovascular Care, 10(Supplement_1), zuab020.035.
Premawardhana ADPE, Lodge A, Sachdev S, Karamanavi E, Kotecha D, Lees JE, Mariscalco G, Rothman A, Gunn J, Samara-Ratna P & Adlam D (2021) Preclinical testing of a novel pericardial left ventricular assist device (PALVAD). European Heart Journal. Acute Cardiovascular Care, 10(Suppl 1).
Fidock B, Archer G, Barker N, Elhawaz A, Al-Mohammad A, Rothman A, Hose R, Hall IR, Grech E, Briffa N , Lewis N et al (2021) Standard and emerging CMR methods for mitral regurgitation quantification. International Journal of Cardiology.
Jones R, Varian F, Alabed S, Morris P, Rothman A, Swift AJ, Lewis N, Kyriacou A, Wild JM, Al‐Mohammad A , Zhong L et al (2020) Meta‐analysis of echocardiographic quantification of left ventricular filling pressure. ESC Heart Failure. View this article in WRRO
Goh ZM, Alabed S, Shahin Y, Rothman AMK, Garg P, Lawrie A, Capener D, Thompson AAR, Alandejani FAA, Johns CS , Lewis RA et al (2020) Right Ventricular Adaptation Assessed Using Cardiac Magnetic Resonance Predicts Survival in Pulmonary Arterial Hypertension. JACC: Cardiovascular Imaging.
Premawardhana ADPE, Lodge AD, Sachdev S, Karamanavi E, Kotecha D, Rothman AD, Samara-Ratna P & Adlam D (2020) Pericardial Left Ventricular Assist Device (PALVAD) development via large animal and cadaveric models. European Heart Journal, 41(Supplement_2).
Hemnes A, Rothman AMK, Swift AJ & Zisman LS (2020) Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension. Pulmonary Circulation, 10(4).
Premawardhana D, Lodge A, Sachdev S, Karamanavi E, Kotecha D, Lees J, Rothman A, Gunn J, Samara-ratna P & Adlam D (2020) TCT CONNECT-180 Novel Pericardial Left Ventricular Assist Device (PALVAD) Assessment via Large Animal and Cadaveric Models. Journal of the American College of Cardiology, 76(17), B77-B77.
Klinke A, Schubert T, Müller M, Legchenko E, Zelt JGE, Shimauchi T, Napp LC, Rothman AMK, Bonnet S, Stewart DJ , Hansmann G et al (2020) Emerging therapies for right ventricular dysfunction and failure. Cardiovascular Diagnosis and Therapy, 10(5), 1735-1767.
Archer GT, Elhawaz A, Barker N, Fidock B, Rothman A, van der Geest RJ, Hose R, Briffa N, Hall IR, Grech E , Bissell M et al (2020) Validation of four-dimensional flow cardiovascular magnetic resonance for aortic stenosis assessment. Scientific Reports, 10(1). View this article in WRRO
Barker N, Zafar H, Fidock B, Elhawaz A, Al-Mohammad A, Rothman A, Kiely DG, van der Geest RJ, Westenberg J, Swift AJ , Wild JM et al (2020) Age-associated changes in 4D flow CMR derived tricuspid valvular flow and right ventricular blood flow kinetic energy. Scientific Reports, 10(1). View this article in WRRO
Rothman A, Kiely D, Vachiery J-L, Howard LS, MIkhail GW, Lang IM, Jonas M, Shav D, Shabtay O, Avriel A , Lewis GD et al (2020) Intravascular ultrasound pulmonary artery denervation to treat pulmonary arterial hypertension (TROPHY1): multicenter, early feasibility study. JACC: Cardiovascular Interventions, 13(8), 989-999. View this article in WRRO
Toshner M & Rothman A (2020) IL-6 in pulmonary hypertension: why novel is not always best. European Respiratory Journal, 55(4), 2000314-2000314.
Lewis RA, Johns CS, Cogliano M, Capener D, Tubman E, Elliot CA, Charalampopoulos A, Sabroe I, Thompson AAR, Billings CG , Hamilton N et al (2020) Identification of cardiac MRI thresholds for risk stratification in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine, 201(4), 458-468. View this article in WRRO
Rothman AMK, MacFadyen J, Thuren T, Webb A, Harrison DG, Guzik TJ, Libby P, Glynn RJ & Ridker PM (2020) Effects of interleukin-1β Inhibition on blood pressure, incident hypertension, and residual inflammatory risk. Hypertension, 75(2), 477-482. View this article in WRRO
Cowie MR, Groote P, McKenzie S, Brett M & Adamson PB (2020) Rationale and design of the CardioMEMS Post‐Market Multinational Clinical Study: COAST. ESC Heart Failure, 7(3), 865-872.
Arnold ND, Pickworth JA, West LE, Dawson S, Carvalho JA, Casbolt H, Braithwaite AT, Iremonger J, Renshall L, Germaschewski V , McCourt M et al (2019) A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension. Nature Communications, 10(1). View this article in WRRO
Morris PD, Gosling R, Rothman A, Iqbal J, Chiastra C, Colombo M, Migliavacca F, Banning A & Gunn JP (2019) The double-kissing nano-crush for bifurcation lesions : development, bioengineering, fluid dynamics and initial clinical testing. Canadian Journal of Cardiology. View this article in WRRO
Fidock B, Barker N, Balasubramanian N, Archer G, Fent G, Al-Mohammad A, Richardson J, O'Toole L, Briffa N, Rothman A , van der Geest R et al (2019) A systematic review of 4D-flow MRI derived mitral regurgitation quantification methods. Frontiers in Cardiovascular Medicine, 6. View this article in WRRO
Middleton JT, Maulik A, Lewis R, Kiely DG, Toshner M, Charalampopoulos A, Kyriacou A & Rothman A (2019) Arrhythmic burden and outcomes in pulmonary arterial hypertension. Frontiers in Medicine, 6. View this article in WRRO
Rothman A, Jonas M, Castel D, Tzafriri AR, Traxler H, Shav D, Leon MB, Ben-Yehuda O & Rubin L (2019) Pulmonary artery denervation using catheter based ultrasonic energy.. EuroIntervention. View this article in WRRO
Billings CG, Lewis R, Hurdman JA, Condliffe R, Elliot C, Thompson AAR, Smith IA, Austin M, Armstrong IJ, Hamilton N , Charalampopoulos A et al (2019) Express: The incremental shuttle walk test predicts mortality in non-group 1 pulmonary hypertension: results from the ASPIRE Registry.. Pulmonary Circulation. View this article in WRRO
Shahin Y & Rothman AM (2019) Commentary on: evaluation of a newly developed 2D parametric parenchymal blood flow technique with an automated vessel suppression algorithm in patients with chronic thromboembolic pulmonary hypertension undergoing balloon pulmonary angioplasty. Clinical Radiology, 74(6), 435-436.
Barker N, Fidock B, Johns CS, Kaur H, Archer G, Rajaram S, Hill C, Thomas S, Karunasaagarar K, Capener D , Al-Mohammad A et al (2019) A Systematic Review of Right Ventricular Diastolic Assessment by 4D Flow CMR. BioMed Research International, 2019. View this article in WRRO
Quadery SR, Swift AJ, Billings C, Thompson AAR, Elliot CA, Hurdman J, Charalampopoulos A, Sabroe I, Armstrong I, Hamilton N , Sephton P et al (2018) The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 52(3). View this article in WRRO
Crossman D & Rothman AMK (2018) Interleukin-1 beta inhibition with canakinumab and reducing lung cancer—subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS). Journal of Thoracic Disease, 10(S26), S3084-S3087.
Alfaidi MA, Chamberlain J, Rothman A, Crossman D, Villa‐Uriol MC, Hadoke P, Wu J, Schenkel T, Evans PC & Francis SE (2018) Dietary Docosahexaenoic Acid Reduces Oscillatory Wall Shear Stress, Atherosclerosis, and Hypertension, Most Likely Mediated via an IL‐1–Mediated Mechanism. Journal of the American Heart Association, 7(13). View this article in WRRO
Rothman AMK, Morton AC, Crossman DC & Investigators MRC-ILAH (2018) Canakinumab for Atherosclerotic Disease. The New England journal of medicine, 378(2), 196-200. View this article in WRRO
Michie S, Carey RN, Johnston M, Rothman AJ, de Bruin M, Kelly MP & Connell LE (2018) From Theory-Inspired to Theory-Based Interventions: A Protocol for Developing and Testing a Methodology for Linking Behaviour Change Techniques to Theoretical Mechanisms of Action. Annals of Behavioral Medicine, 52(6), 501-512.
Rothman AM & Crossman D (2017) The Canakinumab Antiinflammatory Thrombosis Outcome Study Trial—The Starting Gun Has Fired. Journal of Thoracic Disease, 9, 4922-4925. View this article in WRRO
Zhang H-D, Lv Z-C, Wang L-T, Rothman A, Lian T-Y, He Y-Y, Wu Y, Lawrie A, Beghetti M & Jing Z-C (2017) Prognostic Significance of Reduced Blood Pressure Response to Exercise in Pediatric Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 196(11). View this article in WRRO
Pickworth JA, Rothman A, Iremonger J, Casbolt H, Hopkinson K, Hickey P, Gladson S, Shay S, Morrell N, Francis S , West JD et al (2017) Differential IL-1 signaling induced by BMPR2 deficiency drives pulmonary vascular remodeling. Pulmonary Circulation. View this article in WRRO
Swift AJ, Capener D, Johns C, Hamilton N, Rothman A, Elliot C, Condliffe R, Charalampopoulos A, Rajaram S, Lawrie A , Campbell MJ et al (2017) Magnetic Resonance Imaging in the Prognostic Evaluation of Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 196(2). View this article in WRRO
Billings CG, Hurdman JA, Condliffe RA, Elliot CA, Smith IA, Austin M, Armstrong IJ, Hamilton N, Charalampopoulos A, Sabroe I , Swift AJ et al (2017) Incremental Shuttle Walking Test Distance and Autonomic Dysfunction Predict Survival in Pulmonary Arterial Hypertension. The Journal of Heart and Lung Transplantation. View this article in WRRO
Hsiao ST, Spencer T, Boldock L, Prosseda SD, Xanthis I, Tovar-Lopez FJ, Van Beusekom HMM, Khamis RY, Foin N, Bowden N , Hussain A et al (2016) Endothelial repair in stented arteries is accelerated by inhibition of Rho-associated protein kinase. Cardiovascular Research, 112(3), 689-701. View this article in WRRO
Rothman AM, Rowlands DJ & Lawrie A (2016) miRNA-140-5p: new avenue for pulmonary arterial hypertension drug development?. Epigenomics. View this article in WRRO
Rothman AM, Arnold N, Pickworth J, Iremonger J, Ciuclan L, Allan R, Guth-Gundel S, Southwood M, Morrell N, Thomas M , Francis S et al (2016) MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension. Journal of Clinical Investigation, 126(7), 2495-2508. View this article in WRRO
Chen S-L, Zhang H, Xie D-J, Zhang J, Zhou L, Rothman AMK & Stone GW (2016) Response to Letter Regarding Article, “Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes: Phase II Results From the Pulmonary Artery Denervation-1 Study”. Circulation: Cardiovascular Interventions, 9(1).
Zhou L, Zhang J, Jiang X-M, Xie D-J, Wang J-S, Li L, Li B, Wang Z-M, Rothman AMK, Lawrie A & Chen S-L (2015) Pulmonary Artery Denervation Attenuates Pulmonary Arterial Remodeling in Dogs With Pulmonary Arterial Hypertension Induced by Dehydrogenized Monocrotaline. JACC: Cardiovascular Interventions, 8(15), 2013-2023.
Rothman AMK, Arnold ND, Chang W, Watson O, Swift AJ, Condliffe R, Elliot CA, Kiely DG, Suvarna SK, Gunn J & Lawrie A (2015) Pulmonary Artery Denervation Reduces Pulmonary Artery Pressure and Induces Histological Changes in an Acute Porcine Model of Pulmonary Hypertension. Circulation: Cardiovascular Interventions, 8(11), e002569-e002569. View this article in WRRO
Chen S-L, Zhang H, Xie D-J, Zhang J, Zhou L, Rothman AMK & Stone GW (2015) Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes. Circulation: Cardiovascular Interventions, 8(11). View this article in WRRO
Parviz Y, Rothman A & Cooke CJ (2014) Audit of cardiac catheterisation in a DGH: implications for training and patient safety. British Journal of Cardiology, 21, 118-119.
Rothman AMK, Chico TJA & Lawrie A (2014) MicroRNA in pulmonary vascular disease.. Prog Mol Biol Transl Sci, 124, 43-63.
Morton A, Rothman AM, Greenwood JP, Gunn JP, Chases A, Clarke B, Hall AS, Fox K, Folev C, Banya W , Wang D et al (2013) The Effect of Interleukin-1 Receptor Antagonist Therapy on Markers of Inflammation in Non-ST Elevation Acute Coronary Syndromes: The MRC-ILA Heart Study. CIRCULATION, 128(22). View this article in WRRO
Watson O, Novodvorsky P, Gray C, Rothman AMK, Lawrie A, Crossman DC, Haase A, McMahon K, Gering M, Van Eeden FJM & Chico TJA (2013) Blood flow suppresses vascular Notch signalling via dll4 and is required for angiogenesis in response to hypoxic signalling.. Cardiovasc Res, 100(2), 252-261. View this article in WRRO
Rothman AJ, Sheeran P & Wood W (2009) Reflective and Automatic Processes in the Initiation and Maintenance of Dietary Change. Annals of Behavioral Medicine, 38(S1), 4-17.
Wang T, Waters CT, Rothman AMK, Jakins TJ, Römisch K & Trump D (2002) Intracellular retention of mutant retinoschisin is the pathological mechanism underlying X-linked retinoschisis. Human molecular genetics, 11(24), 3097-3105.
Kendrew R, Ajraoui S, Beaudet A, Kelly K, Kiely DG, Rothman A, Varian F, Davis S & Pillai N () Relevance of patient-centered actigraphy measures in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a qualitative interview study. BMC Pulmonary Medicine, 24(1).
Sammut MA, Conway D, Iqbal J, Krishnamurthy A, Morgan KP, Morris PD, Richardson JD, Rothman AMK, Gunn JP & Storey RF () Duration of triple antithrombotic therapy and clinical outcomes after percutaneous coronary intervention in atrial fibrillation. Expert Review of Cardiovascular Therapy, 1-7.
Webb AJS, Birks J, Feakins KA, Lawson A, Dawson J, Rothman AMK, Werring DJ, Llwyd O, Stewart C & Thomas J () Cerebrovascular Effects of Sildenafil in Small Vessel Disease: The OxHARP Trial. Circulation Research.
Joyal-Desmarais K, Rothman AJ, Evans EH, Araújo-Soares V & Sniehotta FF () Furthering Scientific Inquiry for Weight Loss Maintenance: Assessing the Psychological Processes Impacted by a Low intensity Technology-Assisted Intervention (NULevel Trial). Annals of Behavioral Medicine.
Zafar H, Neelam-Naganathan D, Middleton JT, Binmahfooz SK, Battersby C, Rogers D, Swift AJ & Rothman AMK () Anatomical characterization of pulmonary artery and implications to pulmonary artery pressure monitor implantation. Scientific Reports, 13(1).
Choma EA, Hayes S, Lewis BA, Wyman JF, Rothman AJ, Guan W & McMahon S () Technical Assistance Received by Older Adults to Use Commercially Available Physical Activity Monitors: An Ad-hoc Study of the Ready Steady 3.0 Trial (Preprint). JMIR mHealth and uHealth.
McMahon SK, Macheledt K, Choma EA, Lewis BA, Guan W, Wyman JF & Rothman AJ () Rethinking how and when to report descriptions of behavior change content within interventions: a case study of an ongoing physical activity trial (ready steady 3.0). Translational Behavioral Medicine.
Dauw J, Sokolski M, Middleton JT, Nijst P, Dupont M, Forouzan O, Rothman AMK, Ruschitzka F, Flammer AJ & Mullens W () Ambulatory haemodynamic‐guided management reduces heart failure hospitalizations in a multicentre European heart failure cohort. ESC Heart Failure.
Shahin Y, Alabed S, Alkhanfar D, Tschirren J, Rothman AMK, Condliffe R, Wild JM, Kiely DG & Swift AJ () Quantitative CT Evaluation of Small Pulmonary Vessels Has Functional and Prognostic Value in Pulmonary Hypertension. Radiology.
Alabed S, Alandejani F, Dwivedi K, Karunasaagarar K, Sharkey M, Garg P, de Koning PJH, Tóth A, Shahin Y, Johns C , Mamalakis M et al () Validation of Artificial Intelligence Cardiac MRI Measurements: Relationship to Heart Catheterization and Mortality Prediction. Radiology.
Alkhanfar D, Shahin Y, Alandejani F, Dwivedi K, Alabed S, Johns C, Lawrie A, Thompson AAR, Rothman AMK, Tschirren J , Uthoff JM et al () Severe pulmonary hypertension associated with lung disease is characterised by a loss of small pulmonary vessels on quantitative CT. ERJ Open Research, 00503-2021.
Alandejani F, Hameed A, Tubman E, Alabed S, Shahin Y, Lewis RA, Dwivedi K, Mahmood A, Middleton J, Watson L , Alkhanfar D et al () Imaging and Risk Stratification in Pulmonary Arterial Hypertension: Time to Include Right Ventricular Assessment. Frontiers in Cardiovascular Medicine, 9.
Wang SD, Intille SS, Ponnada A, Do B, Rothman AJ & Dunton GF () Investigating Microtemporal Processes Underlying Health Behavior Adoption and Maintenance: Protocol for an Intensive Longitudinal Observational Study (Preprint). JMIR Research Protocols.
Swift AJ, Wilson F, Cogliano M, Kendall L, Alandejani F, Alabed S, Hughes P, Shahin Y, Saunders L, Oram C , Capener D et al () Repeatability and sensitivity to change of non-invasive end points in PAH: the RESPIRE study. Thorax.
Bekfani T, Fudim M, Cleland JGF, Jorbenadze A, Haehling S, Lorber A, Rothman AM, Stein K, Abraham WT, Sievert H & Anker SD () A Current and Future Outlook on Upcoming Technologies in the Remote Monitoring of Patients with Heart Failure. European Journal of Heart Failure.
Lewis RA, Billings CG, Hurdman JA, Smith IA, Austin M, Armstrong IJ, Middleton J, Rothman AMK, Harrington J, Hamilton N , Hameed AG et al () Maximal Exercise Testing Using the Incremental Shuttle Walking Test Can Be Used to Risk Stratify Patients with Pulmonary Arterial Hypertension. Annals of the American Thoracic Society.
Coghlan JG, Rothman AMK & Hoole SP () Balloon Pulmonary Angioplasty: State of the Art. Interventional Cardiology Review, 16.
Garg P, Wood S, Swift AJ, Fent G, Lewis N, Rogers D, Rothman A, Charalampopoulos A & Al‐Mohammad A () Clinical predictors of all‐cause mortality in patients presenting to specialist heart failure clinic with raised NT‐proBNP and no heart failure. ESC Heart Failure. View this article in WRRO
Sumaya W, Parker WAE, Judge HM, Hall IR, Orme RC, Adam Z, Richardson JD, Rothman AMK, Morgan KP, Gunn JP & Storey RF () Prolonged enoxaparin therapy compared with standard-of-care antithrombotic therapy in opiate-treated patients undergoing primary percutaneous coronary intervention. Platelets. View this article in WRRO
Mullens W, Sharif F, Dupont M, Rothman AMK & Wijns W () Digital health care solution for proactive heart failure management with the Cordella Heart Failure System : results of the SIRONA first‐in‐human study. European Journal of Heart Failure. View this article in WRRO
Swift AJ, Dwivedi K, Johns C, Garg P, Chin M, Currie BJ, Rothman AMK, Capener D, Shahin Y, Elliot CA , Charalampopolous T et al () Diagnostic accuracy of CT pulmonary angiography in suspected pulmonary hypertension. European Radiology. View this article in WRRO
Rothman AM & Lawrie A () mir-140-5p and SMURF1 regulate pulmonary arterial hypertension. Journal of Clinical Investigation.
Novodvorsky P, Watson O, Gray C, Wilkinson RN, Reeve S, Smythe C, Beniston R, Plant K, Maguire R, M. K. Rothman A , Elworthy S et al () klf2ash317 Mutant Zebrafish Do Not Recapitulate Morpholino-Induced Vascular and Haematopoietic Phenotypes. PLoS ONE, 10(10). View this article in WRRO
Garg P, Archer G, Elhawaz A, Zafar H, Swift A, Rothman A, Gunn J & Hose R () Left ventricular blood flow kinetic energy is associated with the six-minute walk test and LV remodelling post valvular intervention in aortic stenosis.. Quantitative imaging in medicine and surgery. View this article in WRRO
Rothman AMK, Arnold ND, Abou-Hanna J, Forouzan O, Swift AJ, Dahaghin P, Konganige S, Middleton JT, Zafar H, Suvarna SK , Kiely DG et al () Feasibility and safety of a telemetric pulmonary artery pressure monitoring system in acute and chronic porcine models of pulmonary hypertension.

Conference proceedings papers

Reddy SA, Middleton JT, Nethercott SL, Polwarth GJ, Pepke-Zaba J, Martin CA, Rothman AMK & Toshner MR (2023) S38 Incidence and phenotypic predictors of arrhythmias in idiopathic pulmonary arterial hypertension. ‘Right here, right now’ – Bench to bedside in pulmonary vascular disease
Durrington C, Hurdman J, Armstrong I, Charalampopoulos A, Condliffe R, Elliot C, De-Fonseka D, Hameed AG, Hamilton N, Hill C , Maclean R et al (2023) Systematic Follow-up of Patients Following Acute Pulmonary Embolism Identifies High Incidence of Chronic Thromboembolic Pulmonary Hypertension: ASPIRE CTEPH. D106. HOT OFF THE PRESSES! LATE BREAKERS IN PULMONARY VASCULAR DISEASE
Durrington C, Battersby C, Holt L, Fairman A, salisbury T, Turton H, Watson L, Hameed A, Charalampopoulos A, Elliot C , Rothman A et al (2023) Assessing the Repeatability of NT-proBNP Testing Using Laboratory and Point of Care Testing in PAH (REPEAT-PAH). B57. INTERMEDIATES, CORRELATES, AND SURROGATES, OH MY!: NOVEL END POINTS AND ASSESSMENTS IN PVD
Alabed S, Garg P, Alandejani F, Dwivedi K, Maiter A, Karunasaagarar K, Rajaram S, Hill C, Thomas S, Gossling R , Sharkey M et al (2023) 33 Cardiac MRI thresholds for improvement in pulmonary arterial hypertension. Abstracts
Haque A, Charalampopoulos A, Dwivedi K, Elliot C, Hameed A, Hamilton N, Lewis R, Ramjug S, Rothman A, Thompson R , Swift A et al (2022) New diagnostic criteria and PVR thresholds in SSc-associated PH: Insights from the ASPIRE registry. 13.01 - Pulmonary hypertension
Alabed S, Dwivedi K, Durrington C, Alandejani F, Lewis R, Eelliot C, Charalampopoulos A, Thompson R, Hameed A, Rothman A , Armstrong I et al (2022) Correlation of emPHasis-10 with clinical tests: insights from the ASPIRE registry. 13.01 - Pulmonary hypertension
Haque A, Divwedi K, Lewis R, Charalampopoulos A, Elliot C, Hameed A, Hamilton N, Ramjug S, Rothman A, Swift A , Thompson R et al (2022) The effect of parenchymal lung disease on patient characteristics and outcome in SSc-PH: Insights from the ASPIRE registry. 13.01 - Pulmonary hypertension
Durrington C, Armstrong I, Charalampopoulos A, Condliffe R, Devey T, Elliot C, Hameed A, Hamilton N, Hill C, Hurdman J , Lewis RA et al (2022) S93 Systematic follow-up of patients following acute pulmonary embolism is associated with an increased incidence of chronic thromboembolic pulmonary hypertension and less severe disease. ‘The Sixth Sense’ – Prognostication in pulmonary vascular disease
Middleton JT, Binmafooz S, Zafar H, Patel J, Giri D, Battersby C, Toshner M, Reddy A, Lewis R, Durrington C , Swift A et al (2022) S92 Remote monitoring enabled evaluation of risk and physiological response to therapeutic escalation and clinical worsening in patients with pulmonary hypertension. ‘The Sixth Sense’ – Prognostication in pulmonary vascular disease
Goh ZM, Balasubramanian N, Alabed S, Dwivedi K, Shahin Y, Rothman AMK, Garg P, Lawrie A, Capener D, Thompson AAR , Alandejani F et al (2022) S90 Right ventricular remodelling assessed using cardiac magnetic resonance predicts survival and treatment response in pulmonary arterial hypertension. ‘The Sixth Sense’ – Prognostication in pulmonary vascular disease
Battersby CP, Middleton JT, Zafar H, Binmahfooz SK, Patel J, Neelam-Naganathan D, Toshner M, Reddy A, Lewis R, Watson L , Swift A et al (2022) P81 Effect of COVID-19 infection and preventive public health measures on haemodynamics, activity and quality of life in patients with pulmonary arterial hypertension. ‘Contagion’ – The impact of COVID-19
Durrington C, Battersby C, Holt L, Fairman A, Salisbury T, Turton H, Watson L, Hameed AG, Charalampopoulos A, Elliot CA , Rothman AMK et al (2022) P38 Assessing the repeatability of NT-proBNP testing using laboratory and point of care testing in PAH (REPEAT-PAH). ‘Mission (Im)possible I’ – Pulmonary vascular disease
Patel J, Middleton J, Battersby C, Zafar H, Binmahfooz S, Neelam-Naganathan D, Toshner M, Reddy A, Lewis R, Watson L , Swift A et al (2022) S91 Remote monitored physical activity is related to established measures of clinical risk in patients with pulmonary arterial hypertension. ‘The Sixth Sense’ – Prognostication in pulmonary vascular disease
Alabed S, Dwivedi K, Durrington C, Alandajani F, Condliffe R, Elliot C, Charalampopoulos A, Hameed A, Thompson R, Rothman A , Armstrong I et al (2022) P37 Correlation of emPHasis-10 with clinical tests: insights from the ASPIRE registry. ‘Mission (Im)possible I’ – Pulmonary vascular disease
Middleton JT, Binmahfooz S, Zafar H, Patel J, Giri D, Battersby C, Toshner M, Reddy A, Lewis R, Condliffe R , Elliot C et al (2022) Abstract 13553: Remote Monitoring of the Haemodynamic Response to Clinically Indicated Therapeutic Escalation and Clinical Worsening Events in Patients With Pulmonary Arterial Hypertension. Circulation, Vol. 146(Suppl_1) (pp a13553-a13553)
Middleton JT, Binmahfooz S, Zafar H, Patel J, Naganathan DGN, Battersby C, Toshner M, Reddy A, Lewis R, Swift AJ , Condliffe R et al (2022) Abstract 13527: The Development of a Remote Pulmonary Arterial Hypertension Risk Score Utilising Remote Monitoring Technology to Monitor Parameters Associated With Mortality in Pulmonary Arterial Hypertension. Circulation, Vol. 146(Suppl_1) (pp a13527-a13527)
Alandejani F, Alabed S, Garg P, Goh ZM, Karunasaagarar K, Sharkey M, Salehi M, Aldabbagh Z, Dwivedi K, Metherall P , Uthoff J et al (2022) Training and Clinical Validation of Artificial Intelligence Derived Right Atrial Cardiovascular Magnetic Resonance Measurements. A105. YOU CAN PREDICT ALL YOU WANT, BUT EVERYONE KNOWS...
Sammut MA, Condliffe R, Hameed A, Rothman AM, Kyriacou A, Lewis RA, Durrington C, Elliot CA, Thompson AA, Sabroe I , Kiely DG et al (2021) Abstract 13581: Heart Rhythm versus Heart Rate Control Strategy in Patients With Pre-Capillary Pulmonary Hypertension and Atrial Arrhythmias. Circulation, Vol. 144(Suppl_1)
Gosling R, Alabed S, Swoboda P, Nagueh SF, Jones R, Rothman A, Wild JM, Kiely DG, Condliffe R, Swift AJ & Garg P (2021) 19 Cardiac magnetic resonance to identify raised left ventricular filling pressure. Abstracts
Middleton J, Zafar H, Kiely DG & Rothman A (2021) 124 Comparing the safety and feasibility of implanting pulmonary artery pressure monitors via the internal jugular vein compared to standard femoral venous access in patients with pulmonary arterial hypertension. Heart failure
Middleton J, Zafar H, Reddy A, Martin C, Thompson R, Swift A, Toshner M, Kiely DG & Rothman A (2021) 121 Effect of UK COVID-19 public health measures on activity and quality of life in patients with pulmonary arterial hypertension. Heart failure
Sammut MA, Condliffe R, Hameed A, Rothman AM, Kyriacou A, Lewis RA, Durrington C, Elliot CA, Thompson AA, Sabroe I & Kiely DG (2021) Heart Rhythm versus Heart Rate Control Strategy in Patients With Pre-Capillary Pulmonary Hypertension and Atrial Arrhythmias. CIRCULATION, Vol. 144
Middleton JT, Konganige S, Dahaghin P, Zafar H, Reddy A, Martin C, Thompson AAR, Swift AJ, Morris P, Condliffe R , Morrell NW et al (2020) Abstract 15636: Effect of COVID-19 Public Health Measures on Activity and Quality of Life in Patients With Pulmonary Arterial Hypertension. Circulation, Vol. 142(Suppl_3) View this article in WRRO
Lewis RA, Kelly T, Drew E, Billings CG, Hurdman J, Smith I, Austin M, Armstrong IJ, Middleton J, Rothman AMK , Harrington J et al (2020) Percent-predicted incremental shuttle walking test distance stratifies risk in pulmonary arterial hypertension. Pulmonary hypertension
Alkhanfar D, Shahin Y, Alandejani F, Alabed S, Johns C, Mk Rothman A, Garg P, Condliffe R, Quadery R, Kiely DG , Wild J et al (2020) Serial cardiac MRI for assessment of cardiac morphology and function in CTEPH patients after PEA or vasodilator therapy. Pulmonary hypertension
Rothman A, Vachiery J-LE, Howard LS, Mikhail G, Lang IM, Jonas M, Kiely DG, Abriel A, Lewis GD, Rosenzweig EB , Kirtane AJ et al (2020) Percutaneous Endovascular Ultrasound Pulmonary Artery Denervation for the Treatment of Pulmonary Arterial Hypertension: 12-Month Results of the Trophy 1 Study. D63. PULMONARY EMBOLISM: CASE REPORTS AND LATE BREAKING
Kiely D, Swift A, Cogliano M, Kendall L, Oram C, Capener D, Rothman A, Garg P, Johns C, Austin M , Pickworth J et al (2019) A prospective study comparing the repeatability and sensitivity to change of non-invasive endpoints in pulmonary arterial hypertension: the RESPIRE study. Pulmonary hypertension
Fidock B, Balasubramanian N, Barker N, Macdonald A, Capener D, Johns C, Karunasaagarar K, Fent G, Al-Mohammad A, Rothman A , Kiely D et al (2019) 284An accurate, multi-parametric cardiovascular magnetic resonance model to predict mean pulmonary artery pressure in pulmonary hypertension. European Heart Journal - Cardiovascular Imaging, Vol. 20(Supplement_2)
Balasubramanian N, Baker N, Fidock B, Macdonald AW, Capener D, Johns CS, Karunasaagarar K, Fent G, Al-Mohammad A, Rothman A , Kiely DG et al (2019) P612Averaged, diastolic mitral inflow velocity mapping versus peak velocity for the assessment of left ventricular haemodynamics. European Heart Journal - Cardiovascular Imaging, Vol. 20(Supplement_2) View this article in WRRO
Barker N, Fidock B, Balasubramanian N, Macdonald AW, Capener D, Johns CS, Karunasaagarar K, Fent G, Al-Mohammad A, Rothman A , Kiely DG et al (2019) P165A novel cardiac magnetic resonance imaging model to predict level of mixed venous oxygen levels in pulmonary hypertension. European Heart Journal - Cardiovascular Imaging, Vol. 20(Supplement_2) View this article in WRRO
Lewis R, Billings C, Hurdman J, Smith I, Austin M, Armstrong I, Swift A, Rothman A, Charalampopoulos A, Sabroe I , Elliot C et al (2019) The Incremental Shuttle Walking Test Can Be Used to Risk Stratify Patients with Pulmonary Hypertension as Per the European Respiratory/Cardiac Society Guidelines. A105. GLORY DAYS: THE LATEST CLINICAL RESEARCH IN PAH
Barker N, Fidock B, Balasubramanian N, Macdonald AW, Capener D, Johns CS, Karunasaagarar K, Fent G, Al-Mohammad A, Rothman A , Kiely DG et al (2019) A novel cardiac magnetic resonance imaging model to predict level of mixed venous oxygen levels in pulmonary hypertension. EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, Vol. 20 (pp 121-121)
Lin J, Iremonger J, Pickworth J, Rothman A, Casbolt H, Arnold N, Elliot C, Condliffe R, Kiely D, Jing ZC & Lawrie A (2018) S43 Circulatory levels of microrna-34a expression identify patients with poor clinical outcome, and regulate pulmonary vascular cell phenotype. Fundamental mechanisms of pulmonary arterial hypertension
Rothman AM, West L, Srivastava S, Quigley C, Southwood M, Lawrie A, Francis S, Morrell N & Rowlands D (2018) Expression of SMURF1 is Increased in Patients With Pulmonary Arterial Hypertension and SiRNA Inhibition of SMURF1 Reduces Pulmonary Artery Smooth Muscle Cell Proliferation. CIRCULATION, Vol. 138
Rothman A, Arnold N, Abou Hanna J, Rowland H, Poff B, Macdonald K, Nagy M, Panian T, Sundaram B, Pham P , Forouzan O et al (2017) P612Feasibility and safety of a wireless pulmonary artery pressure monitoring system in chronic porcine models of pulmonary hypertension. European Heart Journal, Vol. 38(suppl_1) View this article in WRRO
Lin J, Iremonger J, Pickworth J, Rothman A, Casbolt H, Arnold N, Elliot C, Condliffe R, Kiely D & Lawrie A (2016) P245 Whole blood levels of microrna-34a predict survival and regulate genes associated with pulmonary arterial hypertension. Thorax, Vol. 71(Suppl 3) (pp A220.2-A221)
Swift A, Lungu A, Capener D, Hammerton C, Rothman A, Lawrie A, Elliot C, Condliffe R, Kiely D & Wild J (2016) Age is independently associated with pulmonary arterial compliance in health and in patients with pulmonary vascular disease. 4.3 Pulmonary Circulation and Pulmonary Vascular Diseases
Swift A, Lungu A, Capener D, Hammerton C, Rothman A, Lawrie A, Elliot C, Condliffe R, Kiely D & Wild J (2016) Age is independently associated with pulmonary arterial compliance in health and in patients with pulmonary vascular disease. EUROPEAN RESPIRATORY JOURNAL, Vol. 48
Rothman AMK, Arnold ND, Pickworth JA, Iremonger J, Ciuclan L, Allen R, Guth-Gundel S, Southwood M, Morrell NW, Thomas M , Francis SE et al (2016) E microRNA-140-5p and SMURF1 Regulate Pulmonary Arterial Hypertension. Heart, Vol. 102(Suppl 6) (pp A147-A147)
Pickworth J, Shay S, Gladson S, Iremonger J, Rothman AMK, Francis S, West J & Lawrie A (2015) S3 Reduced BMPR2 expression potentiates a pulmonary artery smooth muscle cell specific IL-1ß response. Thorax, Vol. 70(Suppl 3) (pp A5.3-A6)
Rothman AMK, Arnold ND, Pickworth JA, Iremonger J, Ciuclan L, Allen R, Guth-Gundel S, Southwood M, Morrell NW, Francis SE , Rowlands DJ et al (2015) T5 MicroRNA-140–5p Regulates Disease Phenotype in Experimental Pulmonary Arterial Hypertension via SMURF1. Thorax, Vol. 70(Suppl 3) (pp A3.1-A3)
Dawson S, Pickworth J, Rothman A, Iremonger J, Arnold N, Francis S & Lawrie A (2014) T5 Opg Regulates Pulmonary Arterial Smooth Muscle Cell Proliferation And The Expression Of Pah-associated Genes Via Fas. Thorax, Vol. 69(Suppl 2) (pp A2-A3)
Dawson S, Pickworth J, Rothman A, Iremonger J, Arnold N & Lawrie A (2014) 183 Novel OPG Protein Interactions Regulate Survival, Proliferation And Pah-associated Gene Expression in Pulmonary Arterial Smooth Muscle Cells. Heart, Vol. 100(Suppl 3) (pp A102.3-A103), 2 June 2014 - 4 June 2014.
Dawson S, Pickworth J, Rothman A, Iremonger J, Arnold N & Lawrie A (2014) Novel OPG Protein Interactions Regulate Survival, Proliferation and PAH-Associated Gene Expression in Pulmonary Arterial Smooth Muscle Cells.. Heart, Vol. 100(Suppl 3:A102-3.)
Arnold N, Dawson S, Pickworth J, Rothman AMK, Iremonger J, Francis S & Lawrie A (2014) Bone Marrow Derived Osteoprotegerin Drives Experimental Pulmonary Arterial Hypertension In The Murine Sugen/hypoxia Model. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol. 189
Dawson S, Pickworth J, Rothman AMK, Iremonger J, Arnold N & Lawrie A (2014) Novel Osteoprotegerin Protein Interactions Regulate Pulmonary Arterial Smooth Muscle Cell Survival And Proliferation. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol. 189
Rothman AMK, Arnold N, Dawson S, Chang W, Suvarna K, Kiely D, Gunn J & Lawrie A (2014) Radio-Frequency Denervation Of The Pulmonary Artery Reduces Pulmonary Hypertension In An Acute Porcine Model. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol. 189
Morton A, Rothman AM, Greenwood JP, Gunn JP, Chase A, Clarke B, Hall AS, Fox K, Foley C & Banya W (2013) The Effect of Interleukin-1 Receptor Antagonist Therapy on Markers of Inflammation in Non-ST Elevation Acute Coronary Syndromes: The MRC-ILA Heart Study. Circulation, Vol. 128(A14792)
Morton A, Rothman AM, Greenwood JP, Gunn JP, Chase A, Clarke B, Hall AS, Fox K, Foley C & Banya W (2013) The Effect of Interleukin-1 Receptor Antagonist Therapy on Markers of Inflammation in Non-ST Elevation Acute Coronary Syndromes: The MRC-ILA Heart Study. Circulation, Vol. 128(A14792)
Rothman AMK, Morton AC, Chico TJ, Crossman DC & Milo M (2011) PERIPHERAL WHOLE BLOOD MICRORNA SIGNATURE DIFFERENTIATES BETWEEN MYOCARDIAL INFARCTION AND UNSTABLE ANGINA. HEART, Vol. 97(20) (pp 7-7)
Morton AC, Foley C, Rothman A, Gunn J, Greenwood JP, Hall A, Fox K, Lees B, Flather M & Crossman D (2011) INVESTIGATION OF IL-1 INHIBITION IN PATIENTS PRESENTING WITH NON-ST ELEVATION MYOCARDIAL INFARCTION ACUTE CORONARY SYNDROMES (THE MRC ILA HEART STUDY). HEART, Vol. 97 (pp A13-A13)
Trump D, Wang T, Waters CT, Rothman AMK, Jakins TJ & Romisch K (2002) RS1 mutations causing X-linked Juvenile Retinoschisis lead to intracellular retention of mutant retinoschisin.. AMERICAN JOURNAL OF HUMAN GENETICS, Vol. 71(4) (pp 554-554)
Trump D, Wang T, Waters CT, Rothman AMK, Jakins TJ & Romisch K (2002) Intracellular retention of mutant retinoschisin is the pathological mechanism underlying X-linked retinoschisis.. JOURNAL OF MEDICAL GENETICS, Vol. 39 (pp S15-S15)

Website content

(2012) Correction.

Preprints

Varian F, Burney R, Pearson C, Goh ZM, Newman J, Rawlings G, Zafar H, Kiely DG, Thompson AAR, Condliffe R , Toshner M et al (2024) Health-related quality of life in pulmonary arterial hypertension trials: a review and conceptual map, Cold Spring Harbor Laboratory.
Middleton JT, Binmahfooz S, Zafar H, Patel J, Ashraf C, Taylor J, Neelam-Naganathan D, Battersby C, Pearson C, Roddis C , Roman S et al (2023) Remote evaluation of risk and physiological response to therapeutic escalation and clinical worsening in patients with pulmonary hypertension, Cold Spring Harbor Laboratory.
Choma EA, Hayes S, Lewis BA, Wyman JF, Rothman AJ, Guan W & McMahon S (2023) Older Adults' Use of Physical Activity Monitors in an 18-Month Trial: Descriptive Study of Technical Problems and Assistance (Preprint), JMIR Publications Inc..
Zafar H, Neelam-Naganathan D, Middleton JT, Rogers D, Swift AJ, Rothman A, Binmahfooz SK & Battersby C (2022) Pulmonary Artery Anatomical Characterization: Relevance to Pulmonary Artery Pressure Sensors, Research Square Platform LLC.

Teaching interests: I enjoy lecturing clinical cardiology to both undergraduates and post-graduates and I teach clinical skills to medical students and doctors.